Compare AOSL & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AOSL | ANAB |
|---|---|---|
| Founded | 2000 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2007 | 2015 |
| Metric | AOSL | ANAB |
|---|---|---|
| Price | $51.30 | $51.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $24.00 | ★ $71.67 |
| AVG Volume (30 Days) | ★ 1.1M | 559.1K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $342,291,000.00 | $234,603,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.41 | $52.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $17.01 | $17.11 |
| 52 Week High | $54.34 | $73.30 |
| Indicator | AOSL | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 62.64 | 32.87 |
| Support Level | $19.24 | $43.75 |
| Resistance Level | N/A | $57.70 |
| Average True Range (ATR) | 4.39 | 2.79 |
| MACD | 0.66 | -1.07 |
| Stochastic Oscillator | 81.49 | 11.75 |
Alpha & Omega Semiconductor Ltd designs, develops and supplies a portfolio of power semiconductors targeting various applications, including personal computers, flat-panel TVs, LED lighting, smartphones, battery packs, consumer and industrial motor controls and power supplies for TVs, computers, servers and telecommunications equipment. It generates revenue mainly from the sale of power semiconductors, consisting of power discretes and power ICs with a presence in Hong Kong, China, South Korea, the United States and other countries. It operates in one operating segment: the design, development and supply of power semiconductor products for computing, consumer electronics, communication and industrial applications.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).